The Prostate Cancer Charity comments on draft guidance issued
today by the National Institute for Health and Clinical Excellence
(NICE), which proposes that they will not recommend abiraterone - a
life extending treatment for men in the final stages of prostate
cancer - to be made available on the NHS in England and Wales.